Who Owns Kamada Company?

Kamada Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Kamada?

Navigating the complexities of the biopharmaceutical industry requires a deep understanding of company ownership. The Kamada SWOT Analysis can help you understand more about the company. Knowing who owns Kamada, a global biopharmaceutical company, is critical for anyone evaluating its potential. This knowledge unlocks insights into strategic direction, financial stability, and future growth prospects.

Understanding Kamada's ownership structure, which includes its primary shareholders, is essential for investors. This analysis will explore the evolution of Kamada's ownership, from its founding to the present day, including the influence of major shareholders and the impact on the Kamada share price. Discovering who is the CEO of Kamada and the company's headquarters location, along with its manufacturing sites, provides a complete picture of this dynamic company. Whether you're interested in how to buy Kamada stock or seeking Kamada company news, this exploration provides valuable insights.

The story of the Kamada company began in 1990. It was founded by David Tzur, Ralph Hahn, and Kamapharam Ltd. This marked the inception of what would become a significant player in the pharmaceutical industry. The early years set the stage for the company's focus on protein-based therapeutics.

Kamapharam Ltd., a wholly-owned entity of Kibbutz Beit Kama, played a crucial role by providing the initial production facilities. David Tzur led the company from its inception, serving as CEO until July 2015. Ralph Hahn and David Tzur jointly steered the company until early 2013, shaping its early strategic direction.

In 1999, a significant transaction occurred when a company owned by Hahn and another investor acquired a 35% stake for $2.5 million. This early investment was a pivotal moment in the company's financial journey. The focus on orphan diseases was a key element of the founding team's vision.

Key Early Developments

The early ownership structure of the Kamada company involved a mix of founders and strategic investors. The sale of a 35% stake in 1999 was a notable early financing round. The company's initial focus was on developing protein-based therapeutics, particularly for orphan diseases.

• David Tzur served as CEO from 1990 to July 2015.
• Ralph Hahn and David Tzur co-led the company until early 2013.
• Kamapharam Ltd., owned by Kibbutz Beit Kama, provided production facilities.
• The 1999 investment was a key early financial transaction.

Kamada SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of Kamada's ownership reflects its growth from a privately held entity to a publicly traded company. The initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE) in 2005 marked a pivotal moment, followed by a U.S. IPO on Nasdaq in June 2013. This transition allowed Kamada to access broader capital markets and expand its investor base, setting the stage for strategic partnerships and acquisitions.

Key events have significantly impacted Kamada's ownership structure and strategic direction. The acquisition of Baxter's intravenous Alpha-1 Antitrypsin (AAT) product line in 2013 expanded its product portfolio and market presence. The U.S. FDA approval for Glassia in 2015 was a major milestone, marking its entry into the U.S. market. Furthermore, a strategic collaboration with Shire (now Takeda) in 2017 enhanced Kamada's global reach, solidifying its position in the pharmaceutical industry. For more insights, you can explore the Brief History of Kamada.

As of June 5, 2025, Kamada's major shareholders include FIMI Opportunity Funds, holding approximately 38% of the outstanding shares. Other significant institutional investors include Phoenix Holdings Ltd., Renaissance Technologies Llc, and Vanguard. The institutional ownership landscape underscores the company's appeal to a diverse range of investors, from private equity firms to established investment funds. This distribution of ownership impacts corporate governance and strategic decision-making at Kamada.

Key Takeaways on Kamada Ownership

Kamada's ownership structure has evolved significantly since its IPOs. FIMI Opportunity Funds is the controlling shareholder, with a substantial stake influencing the company's direction.

• Institutional investors hold a significant portion of the shares.
• Individual insiders also have a notable ownership percentage.
• Understanding the ownership structure is crucial for assessing Kamada's stability and future prospects.

Kamada PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors significantly shapes the governance of the Kamada company, with representation from major shareholders and independent members. Lilach Asher Topilsky has served as the Chairman of the board of directors since August 2020, and is also a Senior Partner in the FIMI Opportunity Funds, indicating FIMI's strong influence. Ishay Davidi, the Founder and CEO of FIMI Opportunity Funds, has been on the board since December 2019. Additionally, David Tsur, a co-founder, is also a director. Other members include Lilach Payorski, who serves on the Audit Committee and Compensation Committee. This composition reflects a blend of shareholder interests and independent oversight.

The structure of the board, along with the voting power of shareholders, is crucial for understanding the dynamics of . The board's composition and the voting structure collectively influence the company's strategic direction and operational decisions. Shareholders re-elected seven directors at the annual general meeting on December 11, 2024, and approved the re-appointment of the independent registered public accountants. The presence of FIMI Opportunity Funds as the controlling shareholder, with approximately 38% ownership, provides substantial voting power.

The voting structure at generally follows a one-share-one-vote basis, common for publicly traded companies. Shareholders of record as of October 28, 2024, were eligible to vote at the annual general meeting held on December 11, 2024. The significant ownership stake by FIMI Opportunity Funds, with approximately 38%, allows them to substantially influence key decisions, including board appointments and strategic direction. There were no proxy battles or activist investor campaigns reported recently.

Voting Power and Board Influence

The board of directors at includes members from major shareholders, like FIMI Opportunity Funds, and independent members. FIMI's significant ownership gives them substantial voting power. This structure influences key decisions, including board appointments and strategic direction.

• Lilach Asher Topilsky serves as Chairman of the board.
• Ishay Davidi, the Founder and CEO of FIMI Opportunity Funds, is also a director.
• Shareholders re-elected seven directors at the annual general meeting.
• FIMI Opportunity Funds holds approximately 38% of the shares.

Kamada Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Kamada's financial performance has been robust. In 2024, the

Kamada company

Looking ahead,

Kamada pharmaceuticals

While FIMI Opportunity Funds remains the controlling shareholder, the

Kamada ownership

Kamada share price

Kamada investors

Kamada's Financial Performance in 2024

Record revenues of $161.0 million, up 13% year-over-year. Adjusted EBITDA of $34.1 million, a 42% increase. Net income of $14.5 million, a 75% increase. Strong cash balance of $78.4 million.

2025 Outlook

Projected revenues between $178 million and $182 million. Anticipated adjusted EBITDA between $38 million and $42 million. Expected revenue increase of approximately 12%. Expected adjusted EBITDA increase of approximately 17%.

Ownership Trends

FIMI Opportunity Funds remains the controlling shareholder. Institutional ownership changes are evident. Millennium Management Llc and Marshall Wace, Llp increased holdings. Some institutions reduced their stakes.

Strategic Focus for 2025

Securing new business development. In-licensing opportunities. Collaboration and/or merger and acquisition transactions. Generate operational and commercial synergies.

Kamada Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs